Table 1.
Participant Characteristics
| Thiazide diuretic users, sampled from HVH population: | ||
|
| ||
| No T2D | Incident T2D | |
|
|
||
| N=44 | N=44 | |
|
| ||
| Male sex, n (%) | 19 (43) | 22 (50) |
| Age, mean (SD) | 71.9 (9.9) | 67.8 (8.3) |
| Prior AF, MI, VTE, stroke: n (%)‡ | 13 (30) | 13 (30) |
| BMI, mean (SD)‡ | 31.5 (4.1) | 31.5 (3.4) |
| Users of: | ||
| ACE-inhibitor, n (%) | 15 (34) | 13 (30) |
| Ca-channel blocker, n (%) | 3 (7) | 11 (25) |
| Beta blocker, n (%) | 19 (43) | 27 (61) |
| Statin, n (%) | 17 (39) | 23 (52) |
|
| ||
|---|---|---|
| Statin users, sampled from ongoing gene expression studies: | ||
|
| ||
| No T2 | Incident T2D | |
|
|
||
| N=37 | N=19 | |
|
| ||
| Male sex, n (%) | 27 (73) | 9 (47) |
| Age, mean (SD) | 71.4 (8.3) | 68.2 (6.5) |
| Prior AF, MI, VTE, stroke: n (%) | 0 | 0 |
| BMI, mean (SD) | 30.7 (5.6) | 32.4 (4.8) |
| Users of: | ||
| ACE-inhibitor, n (%) | 13 (35) | 9 (47) |
| Ca-channel blocker, n (%) | 6 (16) | 5 (26) |
| Beta blocker, n (%) | 20 (54) | 9 (47) |
| Diuretic, n (%) | 20 (54) | 16 (84) |
‡
Matching factors during subject selection.